Oxurion and Axiodis CRO leverage AI to revolutionize clinical trials

Oxurion NV, through its subsidiary Axiodis CRO, is introducing innovations incorporating artificial intelligence to transform clinical trials. Axiodis CRO is focusing on two major strategic initiatives: the use of digital twins and virtual patients, and the enhancement of its Exagis eCRF solution with AI. These efforts aim to simulate disease progression, refine inclusion criteria, and reduce trial duration.

At the same time, Axiodis is integrating AI building blocks into Exagis to automate data quality control and intelligent validation of adverse event and medication coding. This approach improves the reliability and consistency of collected information while facilitating workflows.

With these initiatives, Oxurion strengthens its position as a key player in the field of clinical data in Europe, while aiming to create a technological ecosystem focused on augmented clinical data.